Parkinson Disease
Conditions
Keywords
Spinal Cord Stimulation System, DBS
Brief summary
The purpose of the STIMO-PARKINSON study is to evaluate the safety and preliminary efficacy of Targeted Epidural Spinal Stimulation (TESS) system to induce modulation in leg muscle recruitment in patients with advanced Parkinson's disease, and its capacity to improve key gait and balance deficits when employed in the context of a rehabilitation process of 3 to 5 months.
Detailed description
The study intervention consists of 7 phases preceded by pre-screening: * enrolment and eligibility * baseline * surgery * main phase of the study * home-use * end of main study phase * (optional and conditional): 3 years follow-up At baseline, general information and Parkinson related medical history are collected. Clinical evaluations are also completed without and with current therapy, (i.e. NO(MED+DBS), and MED+DBS conditions). Finally, quality of life questionnaires are collected for the patient as well as expectations questionnaires for the physiotherapists involved in the study. The main phase of the study consists of: * Stimulation configuration sessions during which TESS protocols will be setup and optimized. This procedure aims to configure the spatial and temporal parameters of TESS that will recruit specific muscle groups. Specific TESS protocols will be configured for various motor tasks which will be used during the rehabilitation phase and clinical evaluations. * TESS-supported rehabilitation sessions during which patients will undergo an in-clinic rehabilitation training regime supported by TESS. * Evaluation sessions during which four clinical evaluation sessions will take place focusing on assessment of locomotion, balance and PD related deficits. The tests will be done when patients are: (i) in NO(MED+DBS) condition (without any therapy, i.e. without medication and DBS OFF) (ii) in MED+DBS condition (the patient's standard therapeutical condition, i.e. usual medication dose and DBS ON) (iii) in TESS+MED condition (usual medication dose, TESS ON, DBS OFF) (iv) in TESS+MED+DBS condition (usual medication dose, TESS ON, DBS ON) Participants are allowed to use the investigational system independently if deemed safe and beneficial as assessed by the Principal Investigator (Home-Use Phase). One year after patient enrolment, the patient will come for follow up visits where he will again perform an evaluation session for each therapy condition as described above, to evaluate the long-term evolution. If the therapy has been safe and beneficial, they can extend their study participation by entering the Follow-Up period of 3 years.
Interventions
PROCEDUREImplantation surgery
The intervention involves the implantation of: * a neurostimulator: the Activa® RC from Medtronic * a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic
Sponsors
Jocelyne Bloch
Ecole Polytechnique Fédérale de Lausanne
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single center, non-randomized, interventional study
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Idiopathic Parkinson's disease with III-IV Hoehn-Yahr stage, exhibiting severe gait difficulties and postural instability * With Medtronic DBS implant and receiving medication for Parkinson's disease * Aged 18 to 80 years * Stable medical, physical and psychological condition as considered by the Investigators in accordance with treating physician and treating neurologist. * Must agree to comply in good faith with all conditions of the study and to attend all required study training and visit * Must provide and sign the study's Informed Consent prior to any study-related procedures
Exclusion criteria
* Severe or chronic medical disorder pre-existing PD diagnosis affecting rehabilitation * Active oncological disease requiring heavy treatments and frequent MRI controls * Having an implanted device that is active (e.g., pacemaker, implantable cardiac defibrillator) whose interference with the investigational system's neurostimulator (Activa RC) is not confirmed safe by the CE-mark of the device, or having an indication that might lead to implantation of such device * Inability to follow study procedures, e.g. due to language problems, psychological disorders, dementia as considered by the Investigators in accordance with treating physician and treating neurologist * Hematological disorders with an increased risk of hemorrhagic event during surgical interventions * Life expectancy of less than 12 months * Pregnant or breast feeding * Participation in another interventional study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Occurence of all SAEs and AEs deemed or related to study procedure or to the study investigational system | Through study completion, an average of 6 months | Evaluate the safety of TESS at supporting locomotor rehabilitation in patients with Parkinson's Disease |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| EMG measurements of muscle recruitment in response to stimulation of increasing amplitudes for different contact configurations | At baseline and during the 5-month TESS-supported rehabilitation phase | Assess the preliminary efficacy outcome of TESS to induce modulations in muscle recruitment selectivity by measuring the EMG response to iterative stimulation pulses of increasing amplitude for different contact configurations |
| Maximum voluntary contraction (MVC) of single joints | At baseline and during the 5-month TESS-supported rehabilitation phase | Assess the preliminary efficacy of TESS on motor performance through changes in single joint leg muscle strength and fatigue |
| Muscle Fatigue Test | At baseline and during the 5-month TESS-supported rehabilitation phase | Measure the time the patient can maintain a certain percentage of his MVC measured in the MED+DBS condition. This is used to assess the preliminary efficacy of TESS on motor performance through changes in single joint leg muscle strength and fatigue |
| 10-meter walk test | At baseline and during the 5-month TESS-supported rehabilitation phase | Assess the preliminary efficacy of TESS on motor performance through changes in gait speed and endurance |
| 6 minute walk test | At baseline and during the 5-month TESS-supported rehabilitation phase | Assess the preliminary efficacy of TESS on motor performance through changes in gait speed and endurance |
| Timed up and Go test and its cognitive version, as custom-made FOG circuit | At baseline and during the 5-month TESS-supported rehabilitation phase | Assess the preliminary efficacy of TESS for alleviating deficits specific to PD related to freezing of gait (FOG) |
| Kinematic analysis | At baseline and during the 5-month TESS-supported rehabilitation phase | Assess the preliminary efficacy of TESS for alleviating deficits specific to PD related to posture using motion sensors acquisition system |
| Mini Balance Evaluation Systems Test (mini-BESTest) | At baseline and during the 5-month TESS-supported rehabilitation phase | Assess the preliminary efficacy of TESS for alleviating deficits specific to PD related to balance |
| Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | At baseline and during the 5-month TESS-supported rehabilitation phase | Assess the preliminary efficacy of TESS for alleviating deficits specific to PD related to motor and non-motor functions. Higher scores indicate greater impact of Parkinson's disease symptoms |
Countries
Switzerland
Contacts
PRINCIPAL_INVESTIGATORJocelyne Bloch, MD
CHUV
Outcome results
None listed